Enhanced Topical Compositions for Hair Growth and Alopecia Treatment

Publication ID: 24-11857556_0006_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Topical Compositions for Hair Growth and Alopecia Treatment,” Published Technical Disclosure No. 24-11857556_0006_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857556_0006_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,556.

Summary of the Inventive Concept

The present invention relates to improved topical compositions and methods for preventing hair loss, androgenic alopecia, and stimulating hair growth, addressing the limitations of existing formulations by incorporating novel penetration enhancers, buffering agents, lipophilic excipients, hydrophilic excipients, viscosity modifying agents, and antioxidants.

Background and Problem Solved

The original patent disclosed topical compositions of dutasteride for hair growth and alopecia treatment. However, these compositions had limitations in terms of skin penetration, stability, and efficacy. The present invention addresses these limitations by introducing new components that enhance the delivery, tolerability, and effectiveness of dutasteride-based topical compositions.

Detailed Description of the Inventive Concept

The new inventive concept comprises topical compositions featuring dutasteride in combination with penetration enhancers (e.g., oleic acid, linoleic acid, glyceryl monolinoleate), buffering agents (e.g., tromethamine, triethanolamine), lipophilic excipients (e.g., isopropyl myristate, cetyl lactate), hydrophilic excipients (e.g., glycerin, sorbitol), viscosity modifying agents (e.g., xanthan gum, carboxy methyl cellulose), and antioxidants (e.g., vitamin E, vitamin C). These components work synergistically to improve the skin penetration, stability, and efficacy of dutasteride, leading to enhanced hair growth and alopecia treatment outcomes.

Novelty and Inventive Step

The new claims introduce novel combinations of components that provide a significant improvement over the original patent's compositions. The use of specific penetration enhancers, buffering agents, and excipients, as well as the incorporation of viscosity modifying agents and antioxidants, constitutes a non-obvious advancement in the field of topical hair growth and alopecia treatments.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include varying the concentration of dutasteride, using different types of penetration enhancers or buffering agents, or incorporating additional active ingredients to enhance the composition's efficacy. Variations of the composition may also include different formulations, such as gels, creams, or ointments, to suit specific user needs and preferences.

Potential Commercial Applications and Market

The enhanced topical compositions and methods of the present invention have significant commercial potential in the hair care and dermatology industries, addressing a large and growing market for hair growth and alopecia treatments. The inventive concept may be of particular interest to companies developing topical therapeutics for androgenic alopecia, as well as to consumers seeking more effective and convenient hair growth solutions.

Field of Art

Pharmaceutical formulation and topical drug delivery, specifically focused on hair loss treatments and 5α-reductase inhibitor compositions

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical formulation scientist with expertise in topical drug delivery, knowledge of excipient interactions, penetration enhancement techniques, and experience developing dermatological compositions

Obviousness Rationale

A PHOSITA would recognize that the PTD's variations represent predictable extensions of the source patent's core composition by systematically exploring known pharmaceutical formulation techniques to improve dutasteride delivery and efficacy. The disclosed penetration enhancers, excipients, and additional agents represent standard optimization strategies routinely employed in topical drug development to enhance absorption, stability, and therapeutic performance.

Obvious Combinations & Variations

Source Patent Element
Dutasteride-based topical composition with medium chain triglycerides and ethanol
PTD Variation
Addition of penetration enhancers like oleic acid and linoleic acid to improve drug absorption
Obviousness Reasoning
Known penetration enhancement techniques for improving lipophilic drug delivery through skin, representing a predictable solution for enhancing drug penetration
Source Patent Element
Base topical composition for hair growth treatment
PTD Variation
Incorporation of buffering agents like tromethamine to modulate pH and improve formulation stability
Obviousness Reasoning
Routine pharmaceutical formulation practice to optimize composition pH and enhance drug stability using well-understood buffering techniques
Source Patent Element
Dutasteride in triglyceride and ethanol base
PTD Variation
Introduction of viscosity modifying agents like xanthan gum to improve application characteristics
Obviousness Reasoning
Predictable design choice to enhance topical composition rheology and user experience using standard pharmaceutical excipients
Source Patent Element
Topical hair loss treatment composition
PTD Variation
Addition of antioxidants like vitamin E to improve formulation stability and potential therapeutic benefits
Obviousness Reasoning
Well-known pharmaceutical strategy to prevent oxidative degradation and potentially enhance therapeutic performance using recognized antioxidant compounds
Source Patent Element
Basic dutasteride topical formulation
PTD Variation
Alternative delivery systems including gels, creams, and specialized application devices
Obviousness Reasoning
Obvious variation representing standard pharmaceutical product development approaches to expand formulation options and user convenience
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in this Published Technical Disclosure would have been obvious to a Person Having Ordinary Skill In The Art at the time of invention, as the modifications represent predictable extensions of the foundational teachings in US Patent 11857556, employing routine pharmaceutical formulation techniques to enhance drug delivery, stability, and therapeutic performance of dutasteride-based compositions.

Original Patent Information

Patent NumberUS 11,857,556
TitleTopical compositions of dutasteride
Assignee(s)SHILPA MEDICARE LIMITED